Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
CVAC Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: November 30, 2025
Report Source: 2025 3rd Quarter Report
CureVac NV. Stock Analysis CVAC
United States Health Care Small Cap Report: CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Read More CureVac NV (CVAC) Chart
Key Statistics of CureVac NV (CVAC)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$4.57Volume
1.15MP/E Ratio (TTM)
5.6552 Week Range
Market Cap
972.78MAvg. Volume
1.31MDividend Yield
-Financial Metrics & Statements of CureVac NV (CVAC)
FAQ's for CureVac NV (CVAC)
- According to Musaffa’s Shariah screening methodology, CureVac NV (CVAC) is currently classified as NOT HALAL as of November 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes CureVac NV using these criteria to determine its compliance status.
- Muslim investors may consider investing in CureVac NV if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of CureVac NV by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of CureVac NV may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of CureVac NV on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.